JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia

  • 0Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
Journal of Personalized Medicine +

|

August 29, 2024

|

August 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Primary tumor location impacts metastatic colorectal cancer (mCRC) treatment outcomes. Right colon cancer (RCC) patients receiving anti-EGFR therapy show significantly worse progression-free survival and overall survival compared to left colon cancer (LCC) patients.

Area Of Science

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background

  • Metastatic colorectal cancer (mCRC) treatment is complex.
  • Primary tumor location (LPT) influences patient prognosis and treatment response.
  • Epidermal Growth Factor Receptor Antibody (anti-EGFR) therapy is a key treatment modality for KRAS wild-type mCRC.

Purpose Of The Study

  • To highlight the prognostic and predictive value of LPT in mCRC.
  • To investigate the role of HER2 overexpression in mCRC patients treated with anti-EGFR therapy.
  • To analyze the impact of LPT on survival outcomes in KRAS wild-type mCRC patients receiving anti-EGFR therapy.

Main Methods

  • Retrospective analysis of 181 patients with KRAS wild-type mCRC who received anti-EGFR therapy.
  • Categorization of patients into left colon cancer (LCC) and right colon cancer (RCC) groups.
  • Multivariate analysis to identify independent predictors of overall survival (OS) and progression-free survival (PFS).

Main Results

  • Patients with KRAS wild-type LCC demonstrated significantly better median OS (43 vs. 33 months) and PFS (6 vs. 3 months) compared to RCC patients.
  • Multivariate analysis identified RCC location, mucinous adenocarcinoma, perineural invasion, and tumors at the resection margin as independent predictors of OS.
  • RCC location and mucinous adenocarcinoma were independently associated with significantly shorter PFS. HER2-positive expression correlated with worse PFS.

Conclusions

  • LPT is a crucial marker for predicting outcomes in KRAS wild-type mCRC patients treated with anti-EGFR therapy.
  • Patients with RCC exhibit significantly shorter PFS and OS compared to LCC patients.
  • Further research is warranted to elucidate the role of HER2 overexpression in wild-type mCRC and its impact on survival.

Keywords: